NNVC stock forecast, quote, news & analysis
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections... Show more
NanoViricides (NNVC) Stock Analysis: Phase II Antiviral Milestones Meet a Tightening Cash Runway
Key Takeaways
- NanoViricides shares traded near $1.30 in late September 2026, a modest single-digit move from roughly $1.25 a month earlier despite sharp intra-period swings.
- The clinical-stage nanomedicine company advanced its lead broad-spectrum antiviral NV-387 into Phase II clinical trials for MPox and Ebola in the Democratic Republic of the Congo.
- Financing remains the central risk, with about $2.79 million in cash as of June 30, 2026 and a disclosed going-concern warning.
- One research initiation report sets a $6.00 price target, reflecting a wide gap between analyst expectations and the current share price.
Current Market Snapshot
NanoViricides, Inc. (NYSE American: NNVC) is a micro-cap biotechnology name whose share price has been volatile around a relatively narrow baseline. In late September 2026, the stock traded near $1.30, within a 52-week range of roughly $0.85 to $2.23 and a market capitalization of approximately $33 million. Over the trailing 30 days, shares moved from a closing level near $1.25 in late August to approximately $1.30, a change of about 4%.
That headline figure understates the intra-period turbulence. The stock drifted lower through early September, touching a low near $1.00 around September 10, before rallying sharply to an intraday peak above $1.70 around September 21 as the company announced the initiation of its MPox Phase II trial. Shares subsequently retraced a portion of those gains. The pattern reflects a small-cap equity that is highly sensitive to clinical and financing headlines.
NanoViricides (NNVC) Business Overview and Competitive Position
NanoViricides is a clinical-stage nano-biopharmaceutical company headquartered in Shelton, Connecticut, founded in 2005 and listed on the NYSE American since 2013. The company develops antiviral therapies using its nanoviricide platform, a host-mimetic nanomedicine approach designed to mimic the receptors viruses use to attach to cells, bind and neutralize virus particles, and resist viral mutation-based escape.
The lead candidate is NV-387, a broad-spectrum antiviral that has completed a Phase I safety and tolerability study in healthy volunteers and is now in Phase II trials for MPox and Ebola. NV-387 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration, and the company is also exploring indications in respiratory viruses, smallpox, and measles. NanoViricides operates its own cGMP-capable manufacturing and R&D facility in Shelton, which supports clinical supply and potential early commercial production. The company licenses its core technology from TheraCour Pharma, Inc.
Recent Developments Driving NNVC
The most significant recent catalysts have been clinical-trial initiations. On September 23, 2026, the company announced that its Phase II clinical trial of NV-387 Oral Gummies for the treatment of MPox began enrollment in the Democratic Republic of the Congo. Less than a week later, the company reported that its Phase II trial of NV-387 as a treatment for the Bundibugyo ebolavirus and other Ebola viruses had started enrollment and dosing of patients.
These milestones were offset by financial disclosures. On September 29, 2026, NanoViricides filed its annual report on Form 10-K for the fiscal year ended June 30, 2026, reporting a narrower net loss per share compared with the prior year but noting cash and equivalents of approximately $2.79 million. Management stated that the company does not have sufficient funding to continue planned operations through September 30, 2027, and disclosed substantial doubt about its ability to continue as a going concern. The company raised approximately $3.8 million in a July 2026 registered direct offering and has access to a $3 million line of credit provided by its founder, though it is actively pursuing additional grant, partnership, and equity financing.
Trending AI Robots
For traders seeking a systematic approach to the market, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading strategies. Tickeron provides hundreds of AI trading bots that trade thousands of tickers, but only the top-performing and most relevant bots are surfaced in this section. Each robot varies in strategy, timeframe, and performance metrics, allowing users to compare approaches suited to different market conditions and risk profiles. The page is designed to help investors identify signal-driven ideas without manual screening. Exploring the platform can provide additional context for how algorithmic models are navigating volatile small-cap names like NNVC.
2026 Outlook and What Investors Should Watch
Looking ahead, the primary drivers for NanoViricides will be clinical and financial. Investors should monitor enrollment progress and any initial safety or efficacy data from the Phase II MPox and Ebola trials, as positive readouts would represent the company's most meaningful potential catalysts. Regulatory milestones, including pursuit of additional orphan drug designations and a pre-IND filing for smallpox under the FDA's Animal Rule, also warrant attention.
On the financial side, the going-concern disclosure means capital-raising activity is likely to remain a recurring theme. Any additional equity offerings under the company's at-the-market facility or registered direct offerings could affect the share count and price. Broader biotech sentiment, interest-rate expectations, and risk appetite for clinical-stage micro-cap names will also shape trading. As with any pre-revenue drug developer, the outcome of clinical trials and the company's ability to secure non-dilutive funding remain the key variables for the stock's trajectory.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NNVC's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Indicator for NNVC moved out of overbought territory on September 22, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 instances where the indicator moved out of the overbought zone. In 23 of the 24 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for NNVC turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 46 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NNVC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
NNVC broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NNVC entered a downward trend on September 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 71 cases where NNVC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on NNVC as a result. In 87 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
NNVC moved above its 50-day moving average on October 13, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NNVC crossed bullishly above the 50-day moving average on September 25, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 23 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 74%.
Following a +15.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where NNVC advanced for three days, in 157 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.409) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. NNVC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NNVC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of anti-viral therapeutics
Industry Biotechnology